AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
AstraZeneca
Neonc Technologies, Inc.
AstraZeneca
Jiangsu HengRui Medicine Co., Ltd.
Daiichi Sankyo
SillaJen, Inc.
Nurix Therapeutics, Inc.
Merck Sharp & Dohme LLC
Toray Industries, Inc
Imugene Limited
Jazz Pharmaceuticals
RemeGen Co., Ltd.
RemeGen Co., Ltd.
Shanghai JMT-Bio Inc.
Sumitomo Pharma America, Inc.
AstraZeneca
Merck Sharp & Dohme LLC
Nektar Therapeutics
Merck Sharp & Dohme LLC
Elevar Therapeutics
Athenex, Inc.
EMD Serono
Chengdu Kanghong Biotech Co., Ltd.
Bristol-Myers Squibb
Eli Lilly and Company
Merrimack Pharmaceuticals
AstraZeneca
Jiangsu HengRui Medicine Co., Ltd.
Daehwa Pharmaceutical Co., Ltd.
AbbVie
Hanmi Pharmaceutical Company Limited
GlaxoSmithKline
Hanmi Pharmaceutical Company Limited